Nifty
Sensex
:
:
11157.80
37593.02
-92.75 (-0.82%)
-441.12 (-1.16%)

Pharmaceuticals & Drugs - Global

Rating :
69/99

BSE: 500257 | NSE: LUPIN

1040.55
21-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  1085.85
  •  1097.85
  •  1030.30
  •  1085.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4118958
  •  43763.93
  •  1122.30
  •  504.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,162.01
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 51,013.03
  • 0.58%
  • 3.79

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.92%
  • 0.77%
  • 9.94%
  • FII
  • DII
  • Others
  • 21.31%
  • 18.52%
  • 2.54%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.21
  • 3.38
  • 2.13

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.71
  • -7.66
  • -4.70

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -1.07
  • -23.79
  • -18.51

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 26.05
  • 25.21
  • 23.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.17
  • 4.03
  • 2.76

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.61
  • 15.13
  • 13.35

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
3,527.86
4,418.38
-20.15%
3,845.74
4,406.32
-12.72%
3,769.27
3,947.33
-4.51%
4,359.65
3,951.06
10.34%
Expenses
3,039.78
3,558.16
-14.57%
3,320.42
3,534.03
-6.04%
3,340.17
3,265.72
2.28%
3,628.62
3,401.42
6.68%
EBITDA
488.08
860.22
-43.26%
525.32
872.29
-39.78%
429.10
681.61
-37.05%
731.03
549.64
33.00%
EBIDTM
13.84%
19.47%
14.01%
19.80%
11.38%
17.27%
16.77%
13.91%
Other Income
43.28
72.21
-40.06%
208.60
86.50
141.16%
93.59
40.20
132.81%
133.27
230.68
-42.23%
Interest
44.26
85.62
-48.31%
107.38
85.52
25.56%
88.60
78.46
12.92%
86.46
73.82
17.12%
Depreciation
214.64
317.09
-32.31%
214.26
280.78
-23.69%
253.23
218.96
15.65%
321.47
265.49
21.09%
PBT
272.46
529.72
-48.57%
495.37
594.73
-16.71%
-107.82
82.17
-
-90.11
441.01
-
Tax
164.32
227.98
-27.92%
105.07
299.84
-64.96%
767.02
245.40
212.56%
34.30
172.91
-80.16%
PAT
108.14
301.74
-64.16%
390.30
294.89
32.35%
-874.84
-163.23
-
-124.41
268.10
-
PATM
3.07%
6.83%
7.11%
6.69%
-23.21%
-4.14%
-2.85%
6.79%
EPS
2.39
6.66
-64.11%
8.61
6.51
32.26%
-19.31
-3.60
-
-2.75
5.92
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
15,502.52
16,836.56
16,718.18
15,804.15
17,494.33
14,255.54
12,770.01
11,286.57
9,641.30
7,082.91
5,818.97
Net Sales Growth
-7.30%
0.71%
5.78%
-9.66%
22.72%
11.63%
13.14%
17.06%
36.12%
21.72%
 
Cost Of Goods Sold
8,818.67
4,962.72
5,234.59
4,733.76
4,660.97
4,010.21
3,806.16
3,485.50
3,221.50
2,364.87
2,060.99
Gross Profit
6,683.85
11,873.84
11,483.59
11,070.39
12,833.36
10,245.33
8,963.85
7,801.07
6,419.80
4,718.04
3,757.98
GP Margin
43.11%
70.52%
68.69%
70.05%
73.36%
71.87%
70.19%
69.12%
66.59%
66.61%
64.58%
Total Expenditure
13,328.99
14,362.21
13,835.96
12,656.64
13,001.19
10,570.19
9,150.42
8,283.78
7,371.41
5,638.20
4,641.13
Power & Fuel Cost
-
443.17
475.51
433.88
377.86
381.27
362.81
334.29
320.22
268.82
205.47
% Of Sales
-
2.63%
2.84%
2.75%
2.16%
2.67%
2.84%
2.96%
3.32%
3.80%
3.53%
Employee Cost
-
2,986.84
3,151.29
2,864.71
2,849.52
2,141.62
1,747.34
1,464.65
1,266.62
969.53
767.56
% Of Sales
-
17.74%
18.85%
18.13%
16.29%
15.02%
13.68%
12.98%
13.14%
13.69%
13.19%
Manufacturing Exp.
-
1,852.21
2,030.42
2,087.52
2,270.19
1,766.00
1,320.55
1,129.59
976.51
753.07
603.68
% Of Sales
-
11.00%
12.14%
13.21%
12.98%
12.39%
10.34%
10.01%
10.13%
10.63%
10.37%
General & Admin Exp.
-
2,798.71
1,429.32
1,219.96
1,306.27
1,195.98
806.87
810.53
692.06
471.23
325.19
% Of Sales
-
16.62%
8.55%
7.72%
7.47%
8.39%
6.32%
7.18%
7.18%
6.65%
5.59%
Selling & Distn. Exp.
-
1,080.45
1,298.77
1,150.61
1,252.77
870.29
835.48
775.26
709.62
647.88
547.48
% Of Sales
-
6.42%
7.77%
7.28%
7.16%
6.10%
6.54%
6.87%
7.36%
9.15%
9.41%
Miscellaneous Exp.
-
238.11
216.06
166.20
283.61
204.82
271.21
283.96
184.88
162.80
547.48
% Of Sales
-
1.41%
1.29%
1.05%
1.62%
1.44%
2.12%
2.52%
1.92%
2.30%
2.25%
EBITDA
2,173.53
2,474.35
2,882.22
3,147.51
4,493.14
3,685.35
3,619.59
3,002.79
2,269.89
1,444.71
1,177.84
EBITDA Margin
14.02%
14.70%
17.24%
19.92%
25.68%
25.85%
28.34%
26.60%
23.54%
20.40%
20.24%
Other Income
478.74
483.76
364.02
150.35
106.51
185.19
239.75
116.48
27.85
14.35
22.19
Interest
326.70
362.98
307.83
204.35
152.53
59.47
9.81
26.65
40.95
35.47
34.48
Depreciation
1,003.60
970.22
1,085.01
1,085.87
912.23
487.13
434.70
260.97
332.19
227.52
171.18
PBT
569.90
1,624.91
1,853.40
2,007.64
3,534.89
3,323.94
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Tax
1,070.71
1,146.56
901.69
288.46
978.51
1,059.34
970.40
962.15
584.16
308.56
114.98
Tax Rate
187.88%
131.36%
59.58%
53.10%
27.68%
31.87%
28.42%
33.98%
30.35%
25.80%
11.56%
PAT
-500.81
-273.72
602.80
247.74
2,549.21
2,255.84
2,403.24
1,836.37
1,314.16
867.65
864.55
PAT before Minority Interest
-497.25
-273.72
611.73
254.83
2,556.38
2,264.60
2,444.43
1,869.50
1,340.44
887.51
879.39
Minority Interest
3.56
0.00
-8.93
-7.09
-7.17
-8.76
-41.19
-33.13
-26.28
-19.86
-14.84
PAT Margin
-3.23%
-1.63%
3.61%
1.57%
14.57%
15.82%
18.82%
16.27%
13.63%
12.25%
14.86%
PAT Growth
-171.39%
-
143.32%
-90.28%
13.00%
-6.13%
30.87%
39.74%
51.46%
0.36%
 
EPS
-11.05
-6.04
13.30
5.47
56.26
49.79
53.04
40.53
29.00
19.15
19.08

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
8,874.06
6,931.57
5,204.18
4,012.89
3,281.08
Share Capital
90.60
90.50
90.42
90.32
90.12
89.90
89.68
89.51
89.33
89.24
Total Reserves
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
8,728.15
6,815.66
5,107.79
3,920.76
3,190.59
Non-Current Liabilities
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
426.15
507.16
572.87
729.96
533.59
Secured Loans
0.70
358.82
448.03
217.15
5.55
12.50
24.42
37.95
27.76
54.25
Unsecured Loans
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
89.33
126.54
209.11
405.20
244.91
Long Term Provisions
296.29
370.79
356.85
308.73
190.00
162.03
132.49
112.45
77.02
37.28
Current Liabilities
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
3,729.23
2,629.55
3,006.92
3,120.30
2,507.37
Trade Payables
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
1,956.06
1,594.13
1,542.88
1,379.28
993.03
Other Current Liabilities
3,124.23
1,279.82
1,517.16
657.97
1,001.27
829.76
287.64
381.25
377.17
201.02
Short Term Borrowings
2,492.75
1,580.21
451.76
2,304.33
1,745.41
369.15
402.38
726.82
1,046.99
791.09
Short Term Provisions
1,195.92
771.66
551.23
569.39
325.67
574.26
345.40
355.97
316.86
522.23
Total Liabilities
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55
Net Block
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
4,368.19
3,355.60
3,000.17
2,749.66
2,056.83
Gross Block
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
6,644.59
5,283.90
4,684.21
4,191.84
2,964.34
Accumulated Depreciation
6,222.39
4,645.17
3,497.87
1,362.37
495.11
2,276.40
1,928.30
1,684.04
1,442.18
907.51
Non Current Assets
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
5,221.19
4,034.77
3,700.29
3,593.12
2,869.33
Capital Work in Progress
939.62
1,639.71
2,598.20
2,133.06
2,702.40
551.87
285.90
310.70
434.84
478.17
Non Current Investment
36.07
185.63
26.71
22.00
14.33
2.51
2.06
2.06
2.80
3.15
Long Term Loans & Adv.
409.58
402.61
383.00
950.76
960.22
274.20
372.99
387.36
396.94
314.42
Other Non Current Assets
72.95
47.13
9.38
7.96
7.70
0.32
0.00
0.00
0.00
4.52
Current Assets
15,413.21
13,853.58
12,209.54
11,952.93
9,887.40
7,832.35
6,100.45
5,143.13
4,342.32
3,504.22
Current Investments
2,338.25
2,109.86
234.86
2,114.13
2.02
1,655.89
176.41
0.00
0.00
0.00
Inventories
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
2,503.56
2,129.45
1,948.93
1,732.67
1,199.96
Sundry Debtors
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
2,656.57
2,464.10
2,186.99
1,780.01
1,255.64
Cash & Bank
2,454.30
987.20
1,408.03
698.17
821.75
481.35
797.50
434.88
402.47
420.14
Other Current Assets
1,717.86
777.47
621.30
533.43
1,241.22
534.98
532.99
572.33
427.17
628.48
Short Term Loans & Adv.
1,180.53
992.48
1,090.65
657.58
761.78
294.91
275.15
339.67
306.12
515.64
Net Current Assets
6,188.01
7,723.71
7,113.99
5,832.34
4,826.23
4,103.12
3,470.90
2,136.21
1,222.02
996.85
Total Assets
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
13,053.54
10,135.22
8,843.42
7,935.44
6,373.55

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
2,733.05
2,003.93
1,250.96
560.04
797.98
PBT
876.78
1,517.17
546.81
3,543.14
3,328.84
3,414.83
2,831.65
1,924.60
1,196.07
994.37
Adjustment
1,574.29
1,588.41
2,782.23
1,214.74
585.35
356.73
410.50
419.58
258.51
207.16
Changes in Working Capital
-471.02
-500.19
-1,019.43
504.62
-3,126.44
-94.91
-466.31
-549.35
-580.65
-159.56
Cash after chg. in Working capital
1,980.05
2,605.39
2,309.61
5,262.50
787.75
3,676.65
2,775.84
1,794.83
873.93
1,041.97
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
-943.60
-771.91
-543.87
-313.89
-243.99
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
-1,054.51
-858.54
-521.86
-741.25
-519.56
Net Fixed Assets
-481.49
-462.56
-1,394.31
-876.24
480.96
-416.45
-309.36
-324.79
-389.71
-558.11
Net Investments
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
-2,280.57
-475.62
-0.75
-6.41
43.19
Others
1,656.44
-794.29
313.11
1,521.90
-7,146.08
1,642.51
-73.56
-196.32
-345.13
-4.64
Cash from Financing Activity
-890.58
744.13
-1,492.10
433.18
5,836.38
-196.89
-857.11
-662.82
108.86
-162.52
Net Cash Inflow / Outflow
1,685.25
-872.37
728.96
2,019.25
-1,507.72
1,481.65
288.28
66.28
-72.35
115.90
Opening Cash & Equivalents
544.06
1,416.43
687.47
780.22
2,095.06
606.62
310.93
244.65
295.88
164.22
Closing Cash & Equivalent
2,229.31
544.06
1,416.43
2,799.47
780.22
2,108.43
606.62
310.93
244.65
295.88

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
272.01
298.87
295.64
295.04
245.21
196.17
154.00
116.13
89.78
73.51
ROA
-1.05%
2.32%
0.99%
10.57%
12.82%
21.08%
19.70%
15.98%
12.40%
15.37%
ROE
-2.12%
4.55%
1.91%
20.98%
22.80%
31.09%
30.89%
29.12%
24.35%
30.08%
ROCE
6.02%
8.48%
3.54%
18.53%
24.38%
40.30%
40.97%
32.70%
24.40%
25.24%
Fixed Asset Turnover
2.12
1.95
2.07
1.62
1.80
2.15
2.28
2.19
1.99
2.10
Receivable days
60.97
65.46
63.76
92.39
92.24
72.65
74.67
74.61
77.76
74.26
Inventory Days
41.97
47.47
49.03
72.15
73.96
65.73
65.48
69.24
75.12
67.69
Payable days
65.89
59.26
68.56
59.62
63.20
64.43
63.78
63.76
64.11
61.46
Cash Conversion Cycle
37.04
53.67
44.23
104.91
103.00
73.94
76.37
80.10
88.76
80.49
Total Debt/Equity
0.51
0.63
0.53
0.60
0.65
0.06
0.09
0.22
0.41
0.35
Interest Cover
3.40
5.92
3.66
24.18
56.89
349.10
107.25
48.00
34.72
29.84

News Update:


  • Lupin launches Leflunomide Tablets
    2nd Sep 2020, 15:59 PM

    The product would be manufactured at Lupin’s Pithampur Unit I facility in India

    Read More
  • Lupin, Mylan launch Nepexto in Germany
    26th Aug 2020, 15:12 PM

    Nepexto is approved for all therapeutic indications of the reference product Enbrel

    Read More
  • Lupin gets USFDA’s nod for Generic Albuterol Sulphate MDI
    25th Aug 2020, 09:50 AM

    The company’s generic Albuterol Sulphate MDI will be manufactured at its Indore facility in India

    Read More
  • Lupin launches Zileuton Extended-Release Tablets
    11th Aug 2020, 15:29 PM

    The product would be manufactured at Lupin’s Nagpur facility, India

    Read More
  • Lupin’s arm inks pact with ForDoz Pharma for two complex injectable assets under development
    7th Aug 2020, 09:14 AM

    Lupin shall leverage its existing commercial infrastructure for marketing and distribution of the two assets

    Read More
  • Lupin - Quarterly Results
    6th Aug 2020, 22:36 PM

    Read More
  • Lupin’s alliance partner Concord gets approval for Mycophenolate Mofetil Tablets
    6th Aug 2020, 15:30 PM

    Mycophenolate Mofetil Tablets USP, 500 mg had annual sales of approximately $96 million in the U.S.

    Read More
  • Lupin launches Favipiravir Drug Covihalt for treatment of mild to moderate COVID-19
    5th Aug 2020, 12:46 PM

    It is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs. 49 per tablet

    Read More
  • Lupin gets tentative approval for Empagliflozin tablets
    4th Aug 2020, 14:53 PM

    Empagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

    Read More
  • Lupin gets USFDA’s tentative nod for Empagliflozin, Linagliptin Tablets
    24th Jul 2020, 09:06 AM

    Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

    Read More
  • Lupin suspends operations at Ankleshwar unit
    15th Jul 2020, 12:19 PM

    The persons are under medical care and the company is carrying out all contact tracing protocol

    Read More
  • Lupin recalls all batches of Metformin Hydrochloride extended-release tablets in US
    8th Jul 2020, 10:14 AM

    This recall is being conducted out of an abundance of caution in line with the ongoing interaction with the U.S. Food and Drug Administration on NDMA impurity levels

    Read More
  • Lupin planning to approach USFDA for re-inspection of key plants
    15th Jun 2020, 11:26 AM

    The Somerset (New Jersey) plant is currently under the official action indicated status

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.